NCT03238365View on ClinicalTrials.gov

Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 10, 2017

Primary Completion Date

July 30, 2019

Study Completion Date

September 8, 2022

Conditions
Lip, Oral Cavity and PharynxLarynx
Interventions
BIOLOGICAL

Nivolumab

Given IV

DRUG

Tadalafil

Given orally

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (2)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

37232

Vanderbilt University, Nashville

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03238365 - Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter